Table 1.
Basic characteristics of the patients (N = 80)
| Sex | |
|---|---|
| Female/Male | 24/56 |
| Age in years, median (range) | 70.5 (44–86) |
| ECOG performance status score | |
| 0–1/2–3 | 53/27 |
| Histology | |
| Squamous/non-squamous | 19/61 |
| Clinical stage at diagnosis | |
| III, IV | 68 |
| Recurrent | 12 |
| Mutation (EGFR/ALK) | |
| Wildtype/unknown | 58 |
| Mutant | 22 |
| Body mass index, kg/m2 | |
| Median (range) | 21.3 (16.5–32.2) |
| Laboratory data, median (range) | |
| C-reactive protein, mg/dL | 0.89 (0.03–11.5) |
| Albumin, g/dL | 3.8 (1.8–4.6) |
| Glasgow prognostic score | |
| 0/1/2 | 42/18/20 |
| Regimen | |
| Pembrolizumab/atezolizumab | 49/31 |
| Administered cycles of pembrolizumab | |
| Median (range) | 3 (1–74) |
| Administered cycles of atezolizumab | |
| Median (range) | 3 (1–40) |
| Smoking status | |
| Current or former/never | 62/18 |
| Tumor proportion score | |
| <50%/≥50% | 52/28 |
| Treatment line | |
| Second/third or subsequent | 39/41 |
ECOG, Eastern Cooperative Oncology Group.